New PBS listings give diabetes management a boost

There are several new listings and expanded indications

Type 2 diabetes management has been given a boost with several new combination therapies and a new long-acting insulin being listed on the PBS.

diabetes insulin

From April 1, doctors will be able to prescribe empagliflozin/linagliptin (Glyxambi) and dapagliflozin/saxagliptin (Qtern).

Each drug combines the actions of a DPP-4 inhibitor and an SGLT-2 inhibitor, which — when used in conjunction with metformin — is likely to improve glucose control and patient compliance, and reduce side effects, says Professor Marck